iCAD Appoints Mark Koeniguer as Chief Commercial Officer
iCAD, Inc. (NASDAQ: ICAD), a pioneer in the development of AI-powered breast health solutions, recently announced the exciting appointment of Mark Koeniguer as their new Chief Commercial Officer (CCO). This strategic move is aimed at accelerating the company’s global growth trajectory in the medical technology sector.
Koeniguer's Role and Responsibilities
In his capacity as CCO, Mark Koeniguer will spearhead revenue growth initiatives for iCAD, both in North America and internationally. He brings with him a wealth of experience exceeding three decades in medical imaging and software as a medical device (SaMD), which will be pivotal in guiding iCAD’s commercial strategies.
Extensive Experience in the Medical Field
Mark's background includes leadership positions at several notable MedTech companies. Most recently, he served as CEO at ScreenPoint Medical, where he remarkably increased the company’s annual recurring revenue by 400%. Under his leadership, two FDA-cleared products were successfully launched, showcasing his ability to transform medical technology enterprises into thriving commercial platforms.
Enhancing iCAD's Market Presence
Dana Brown, President and CEO of iCAD, emphasized Koeniguer's deep understanding of the radiological health market and AI-driven solutions, stating that he is the perfect fit for this critical role. His leadership will be crucial in positioning iCAD to better connect with global health providers, enhancing clinical workflows and patient experiences alike.
The Promise of AI-Powered Solutions
With Koeniguer at the helm, iCAD is poised to not only maintain but also expand its influence in the breast health market. Michelle Strong, the Chief Operations Officer, echoed this sentiment, highlighting that Mark's expertise in diagnostics and breast health solutions is integral to the company's growth trajectory. His insights into imaging workflows will significantly enhance iCAD’s pursuit of bringing its renowned ProFound breast cancer detection and risk assessment solutions to a broader audience.
About iCAD, Inc.
Founded with the mission of creating a world where cancer can’t hide, iCAD is at the forefront of delivering clinically validated AI solutions to medical providers. Their industry-leading ProFound Breast Health Suite is revolutionizing the way mammograms are analyzed, enabling early and accurate cancer detection. Currently, ProFound technology serves medical facilities around the globe, enhancing the lives of millions by ensuring earlier diagnosis and improved patient outcomes.
iCAD estimates having analyzed over 40 million mammograms in the last five years alone, marking a significant impact in the world of breast cancer detection. The solutions are now active in over 50 countries, solidifying iCAD's position as a leader in healthcare innovation.
Frequently Asked Questions
What is Mark Koeniguer's new role at iCAD?
Mark Koeniguer has been appointed as the Chief Commercial Officer (CCO) of iCAD to lead global revenue growth and strategic initiatives.
What experience does Koeniguer bring to iCAD?
Koeniguer brings over 30 years of experience in the medical imaging and digital health fields, including leadership roles at various MedTech companies.
How does Koeniguer’s appointment affect iCAD’s growth?
His extensive background in industry growth and commercial strategy is expected to significantly boost iCAD's global engagement and market presence.
What is the focus of iCAD’s technology?
iCAD focuses on AI-powered solutions that assist in early cancer detection, specifically through their ProFound Breast Health Suite.
Where can iCAD’s solutions be found?
iCAD's ProFound technology is utilized in over 50 countries, with a reach that serves millions of patients worldwide.
